CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaA key role for NF-κB transcription factor c-Rel in T-lymphocyte-differentiation and effector functionsMicroRNA regulation of human protease genes essential for influenza virus replicationA phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene.Research progresses in the pathogenesis of anaplastic large cell lymphoma.CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signalingNuclear factor-κB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1).Human T-cell lymphotropic virus: a model of NF-κB-associated tumorigenesisTRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Inhibitor of apoptosis proteins as intracellular signaling intermediates.Pathobiology of ALK+ anaplastic large-cell lymphoma.The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory ResponsesCD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity.Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation.Copper is a potent inhibitor of both the canonical and non-canonical NFκB pathways.Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.CD30 as a therapeutic target for lymphoma.Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas.Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation.CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.Pathobiology of anaplastic large cell lymphoma.Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.Brentuximab vedotin: clinical updates and practical guidance.
P2860
Q24633761-2D90A05C-0DA0-482F-8F2A-B04B3CC32F2FQ27026685-7CA4E119-DD19-48CA-8A39-03DEFC31483DQ28483683-AB71B898-B0E1-4573-B306-1374CB9E82E1Q33409608-058F0B98-0838-43E1-952E-507D07B8C1DBQ33507899-47037EDD-837B-480A-85F2-74438F6F21CDQ33579708-C2431DA4-A236-4AF4-8131-DFCA1048A248Q33655362-F818C74D-7095-4C9B-91AF-1EA3C34C766CQ33953115-6C579A3B-FAA0-4FB6-97E5-227E18AB5FE2Q34428468-9DBCC3BD-52E7-4AEE-BA2B-D64845E96D86Q34431075-B465A1AF-4BFD-4C17-95B0-1E6283908E29Q35090534-1FCD7EFE-B07C-49B5-A3D1-0883E8636D18Q35125212-75D44B03-EED8-4CD4-8D22-121F0F70F47CQ35607281-7CF076D7-5987-49A0-A665-FBA40C7C67CDQ35804937-2318ECCC-CCEC-4D6B-A2E3-58C05030B934Q36007756-E3EB3A14-F250-4093-98F7-E318CC38C277Q36940326-FCADD0FD-ED2B-4D5D-B174-398D897B5ADFQ36979534-8EA44CB9-F25D-4537-8FEE-CB5F8AB1A6D4Q36998074-6EBC63E2-96F2-412B-B08D-75970CE6C13DQ37179796-C4DA4BE2-6B5C-4CF5-B40B-E0B3B1E8D350Q37698887-C5B1814C-70F3-4BC2-A8D9-2A6444112F66Q37962701-28F6862B-2DF5-414D-9252-4F5DDA9681A3Q38138482-F62F852D-5DC5-4006-8B79-2766D39A58FFQ38912193-4BE4AD11-D194-4716-B348-DA36D7ADC349Q38932868-5AF54BF6-9DD1-401E-A411-2428FB00A5FAQ38957493-7041217F-FC3B-4653-BA1F-6A5A02CCA0C4Q39468269-FF9774EB-490D-4214-A4BC-679726E7AB3EQ39531990-CFE0663F-3AB4-4138-ACDA-D6AD11DEFD7BQ40026531-95EAB422-411B-4353-94B4-603182C47FDFQ40796551-A140583B-AC9F-46FF-BA25-B61F1D7A33B9Q41852473-7EAF1983-7132-48A3-A3CF-65890A4744DBQ42277563-D2717A5F-C6A5-4DE5-A450-48A8F9E57D56Q47102763-D0F0980B-064A-4D34-829A-B4EB8995707FQ49282959-0903AEE7-4A95-446A-A65E-6631FECD9864
P2860
CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CD30 activates both the canoni ...... tic large cell lymphoma cells.
@en
type
label
CD30 activates both the canoni ...... tic large cell lymphoma cells.
@en
prefLabel
CD30 activates both the canoni ...... tic large cell lymphoma cells.
@en
P2093
P2860
P356
P1476
CD30 activates both the canoni ...... tic large cell lymphoma cells.
@en
P2093
Casey W Wright
Colin S Duckett
Julie M Rumble
P2860
P304
10252-10262
P356
10.1074/JBC.M608817200
P407
P577
2007-01-29T00:00:00Z